Rinsulin NPC, 100 me/ml suspension 10 ml

Pharmacotherapeutic group

Hypoglycemic agent, insulin of medium duration of action

Code A10AC01.

Pharmacological properties

Pharmacodynamics.

Rinsulin^® NPX is human insulin produced using recombinant DNA technology. It is a medium-acting insulin. It interacts with specific receptor of outer cytoplasmic cell membrane and forms insulin-receptor complex, which stimulates intracellular processes, including synthesis of several key enzymes (hexokinase, pyruvate kinase, glycogen synthase and others).

Lower blood glucose content is due to increased intracellular transport, increased absorption and assimilation by tissues, stimulation of lipogenesis and glycogenesis and decreased rate of glucose production by liver.

The duration of action of insulin drugs is mainly determined by the speed of absorption, which depends on several factors (e.g., the dose, route and place of administration), so the action profile of insulin is subject to significant variations both in different people and the same person.

On average, after subcutaneous administration, Rinsulin^® NPC begins to act after 1.5 hours, with maximal effect developed between 4 and 12 hours, the duration of action is up to 24 hours.

Pharmacokinetics

The completeness of absorption and onset of effect of insulin depends on the place of administration (stomach, thigh, buttocks), dose (volume of insulin administered), the concentration of insulin in the drug, etc. Distributed irregularly in tissues; does not penetrate through placental barrier and into breast milk. It is broken down by insulinase mainly in the liver and kidneys. It is excreted by the kidneys (30-80%).

Indications

• Diabetes mellitus type 1.
• Diabetes mellitus type 2 stage of resistance to oral hypoglycemic agents, partial resistance to these drugs (when combined therapy), intercurrent diseases.
• Diabetes mellitus type 2 in pregnant women

.

How to take, the dosage

The drug is intended for subcutaneous administration. The dose of the drug is determined by the physician individually in each case, based on the blood glucose concentration. On average, the daily dose of the drug ranges from 0.5 to 1 IU/kg body weight (depends on the individual characteristics of the patient and blood glucose concentration).

Interaction

There are a number of medications that affect the need for insulin.

Special Instructions

Do not use the drug if after shaking the suspension does not become white and uniformly turbid.

Contraindications

• Hypoglycemia.

Side effects

Conditioned by the effect on carbohydrate metabolism: hypoglycemic conditions (pale skin, increased sweating, palpitations, tremors, chills, hunger, agitation, paresthesias of the oral mucosa, weakness, headache, dizziness, decreased visual acuity). Severe hypoglycemia may lead to the development of a hypoglycemic coma.

Overdose

In case of overdose of the drug, hypoglycemic state may develop. Initial symptoms of hypoglycemic state are sudden increased sweating, palpitation, tremor, feeling of hunger, agitation, paresthesias in the mouth, pallor, headache. In severe cases of overdose it is possible to develop hypoglycemic coma.

Treatment: mild hypoglycemia can be treated by the patient himself by taking sugar or carbohydrate-rich foods. In severe cases, 20-40 ml of 40% glucose solution is administered intravenously, 1 mg of glucagon intramuscularly.